<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328337</url>
  </required_header>
  <id_info>
    <org_study_id>2000026149</org_study_id>
    <nct_id>NCT04328337</nct_id>
  </id_info>
  <brief_title>Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism</brief_title>
  <official_title>Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to understand the role of brain glucose transport in individuals&#xD;
      with obesity and the association with cerebral hypometabolism and these individuals' response&#xD;
      to plasma glucose elevations. The main premise is that obesity leads to reduced brain glucose&#xD;
      transport and that we can measure this reduction with magnetic resonance spectroscopy (MRS).&#xD;
      The secondary premises are that this reduction is driven by elevated non esterified fatty&#xD;
      acids which act to turn on specific signaling pathways that regulate brain GLUT1 levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 aims of this study. The intent of aim 1 is to measure the effect of obesity on&#xD;
      glucose transport and metabolism in the human brain. This study aim will be conducted in&#xD;
      non-diabetic, obese individuals and age- and HbA1c-matched normal weight individuals. A total&#xD;
      of 15 non-diabetic - normal weight individuals and 15 obese individuals will be enrolled.&#xD;
&#xD;
      The second aim randomizes 40 non-diabetic, normal weight individuals. The intent of aim 2 is&#xD;
      to determine whether acute elevation of NEFA levels in lean, healthy individuals will alter&#xD;
      cerebral glucose transport. Eligible participants will be randomized (1:1) to receive either&#xD;
      intralipid or normal saline.&#xD;
&#xD;
      The focus of this protocol registration is the randomized portion of the study (aim 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brain glucose transport capacity</measure>
    <time_frame>Through End of Study (Up to 12 hours)</time_frame>
    <description>Measurement of brain glucose transport rates using magnetic resonance spectroscopy (MRS).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Non-diabetic, normal weight individuals receiving Intralipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic, normal weight individuals receiving saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid, 20% Intravenous Emulsion</intervention_name>
    <description>Infusion of Intralipid 20%</description>
    <arm_group_label>Non-diabetic, normal weight individuals receiving Intralipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>saline 30 ml/hr for 12 hours through an IV</description>
    <arm_group_label>Non-diabetic, normal weight individuals receiving saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  HbA1C &lt;6.5%&#xD;
&#xD;
          -  Normal weight individuals: BMI 17-25 kg/m2&#xD;
&#xD;
          -  Obese individuals: BMI &gt;30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt;1.5mg/dL&#xD;
&#xD;
          -  Hematocrit &lt;35% for females and &lt;39% for males&#xD;
&#xD;
          -  ALT and AST &gt;2.5X upper limit of normal&#xD;
&#xD;
          -  Abnormal TSH&#xD;
&#xD;
          -  Abnormal PT/PTT/INR&#xD;
&#xD;
          -  Triglycerides &gt;200 mg/dL&#xD;
&#xD;
          -  Known hepatic, gastrointestinal, renal, neurologic, psychiatric, cerebrovascular&#xD;
             disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Current or past 3 months use of ketogenic diet&#xD;
&#xD;
          -  Use of any medications, vitamins, or supplements that can alter cerebral metabolism or&#xD;
             lipids&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Current or recent steroid use in last 6 months&#xD;
&#xD;
          -  &gt;5% body weight change in last 6 months&#xD;
&#xD;
          -  Illicit drug use/alcoholism&#xD;
&#xD;
          -  Inability to enter MRI/MRS&#xD;
&#xD;
          -  For women: pregnancy, seeking pregnancy, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mari-Lynet Knight</last_name>
    <phone>203-737-6067</phone>
    <email>sugarbrainlab@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari-Lynet Knight</last_name>
      <email>sugarbrainlab@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

